The company utilizes several third-party suppliers and contract manufacturing organizations for its product candidates. CPC Scientific serves as the primary peptide supplier for VXX-401. Wuxi STA provides process development and manufacturing services for oligonucleotides. Pharmaceuticals International, Inc. (Pii) offers fill-finish services. The company maintains multiple agreements with United Biomedical, Inc. (UBI) and its affiliates—UBP, UBIA, and UBIP—for research, development, testing, manufacturing, quality control, validation, GMP warehousing, and supply services related to its COVID-19 program (UB-612) and chronic disease pipeline (UB-312). These agreements have varying expiration dates and payment terms, typically on a cost-plus basis or as specified in individual work orders. UBI also provides administrative services and acts as an agent for certain matters concerning the COVID-19 program. Additionally, the company has a research and development services agreement with UBI that expires in August 2026; fees under this agreement are determined by a joint steering committee and are subject to a quarterly cap.
Vaxxinity Inc's Comment on Supply Chain
The company utilizes several third-party suppliers and contract manufacturing organizations for its product candidates. CPC Scientific serves as the primary peptide supplier for VXX-401. Wuxi STA provides process development and manufacturing services for oligonucleotides. Pharmaceuticals International, Inc. (Pii) offers fill-finish services. The company maintains multiple agreements with United Biomedical, Inc. (UBI) and its affiliates—UBP, UBIA, and UBIP—for research, development, testing, manufacturing, quality control, validation, GMP warehousing, and supply services related to its COVID-19 program (UB-612) and chronic disease pipeline (UB-312). These agreements have varying expiration dates and payment terms, typically on a cost-plus basis or as specified in individual work orders. UBI also provides administrative services and acts as an agent for certain matters concerning the COVID-19 program. Additionally, the company has a research and development services agreement with UBI that expires in August 2026; fees under this agreement are determined by a joint steering committee and are subject to a quarterly cap.
Sources:
Vaxxinity Inc 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Vaxxinity Inc ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
